MedTrace Logo

Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19

NCT04536090 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-03-24

No results posted yet for this study

Summary

This is an open-label, randomized, multi-centre study where hospitalized subjects will be randomized in a 2:1 ratio to receive Isoquercetin (IQC-950AN) in addition to standard of care or standard of care only for 28 days following confirmation of a COVID-19 infection.

Conditions

Interventions

DRUG

Isoquercetin (IQC-950AN)

Isoquercetin will be administered by mouth twice daily for 28 days

Sponsors & Collaborators

  • Pharmascience Inc.

    collaborator INDUSTRY

  • SCiAN Services, Inc.

    collaborator UNKNOWN

  • Quercis Pharma AG

    collaborator INDUSTRY

  • Institut de Recherches Cliniques de Montreal

    lead OTHER

Principal Investigators

  • Michel Chrétien, FRS MD FRCP© · Montreal Clinical Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2022-12-31
Completion
2023-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04536090 on ClinicalTrials.gov